You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

5169 Results
Guidelines and Advice
Status: Current
ID: GL 17-10 v2
Version: 2
Updated
Mar 2025
Document
New
Mar 2025
We present several types of publicly available cancer data and statistics for Ontario in this section, including: incidence (new cases) and...
Dans cette section, nous présentons divers types de données et de statistiques sur le cancer en Ontario accessibles au public, y compris sur: l’...
Drug
Other Name(s): Iressa®
Quick Link(s): Drug Monograph, Patient Info Sheet
Mar 2025
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - In Combination with Pomalidomide and Dexamethasone for Previously Treated Multiple Myeloma
ODB - General Benefit
    dexamethasone
Exceptional Access Program
    pomalidomide - For patients with relapsed and/or refractory multiple myeloma, according to specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
bortezomib,
dexamethasone,
pomalidomide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2025
Document
New
Mar 2025
Document
New
Mar 2025

Pages